Logo image
Back
THE ROLE OF SACUBITRIL/VALSARTAN IN POST-ACUTE MYOCARDIAL INFARCTION (RSVP-AMI TRIAL)
Abstract   Open access   Peer reviewed

THE ROLE OF SACUBITRIL/VALSARTAN IN POST-ACUTE MYOCARDIAL INFARCTION (RSVP-AMI TRIAL)

Mahmoud Abdelnabi, Yehia Saleh, Juthipong Benjanuwattra, Haitham Badran and Abdallah Almaghraby
Journal of the American College of Cardiology, Vol.81(8), pp.1331-1331
03/07/2023
DOI: 10.1016/S0735-1097(23)01775-8
url
https://doi.org/10.1016/S0735-1097(23)01775-8View
Published (Version of record) Open Access

Abstract

Background The aim of this trial was to evaluate the effects of de novo use of Sacubitril-Valsartan (SAC/VAL) in acute myocardial infarction (AMI) in comparison to the conventional therapy in the treatment of post-AMI patients with reduced left ventricular (LV) systolic function. Methods The RSV-PAMI (The role of Sacubitril-Valsartan in Post-Acute Myocardial Infarction NCT03893435) is a randomized open-label interventional clinical trial that included 200 patients with revascularized ST-elevation myocardial infarction (STEMI) and reduced LV systolic function, assessed by transthoracic echocardiography (TTE) randomized to either SAC/VAL or conventional angiotensin receptor blocker (Valsartan). The primary outcomes were in-hospital, major adverse cardiovascular and cerebrovascular events (MACCE) at 6 months, and left ventricular ejection fraction (LVEF) assessed by TTE during hospital stay at 3 and 6 months. Results Demographic, clinical, echocardiographic, and primary endpoint results were demonstrated (Table 1-2) Conclusion In a real-world randomized control trial comparing the effects of SAC/VAL to VAL in post-AMI with reduced LV systolic function, there was no significant difference between both groups regarding in-hospital MACCE while SAC/VAL was associated with significantly lower heart failure incidence and total MACCE at 6 months follow-up.

Details

Metrics

58 Record Views
Logo image